Bank Of Marin Halozyme Therapeutics, Inc. Transaction History

Bank Of Marin

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 13, 2023	SELL	$40.06 - $59.44 $167,811 - $248,994	-4,189 Reduced 21.45%	15,344 $873,000
Q3 2022 Nov 09, 2022	SELL	$38.53 - $51.78 $359,523 - $483,159	-9,331 Reduced 32.33%	19,533 $772,000
Q2 2022 Aug 16, 2022	BUY	$37.35 - $48.3 $132,144 - $170,885	3,538 Added 13.97%	28,864 $1.27 Million
Q1 2022 May 10, 2022	BUY	$31.97 - $41.06 $14,610 - $18,764	457 Added 1.84%	25,326 $1.01 Million
Q4 2021 Feb 15, 2022	BUY	$31.82 - $40.75 $38,915 - $49,837	1,223 Added 5.17%	24,869 $1 Million
Q3 2021 Nov 15, 2021	BUY	$38.47 - $46.42 $160,381 - $193,524	4,169 Added 21.4%	23,646 $962,000
Q2 2021 Aug 09, 2021	BUY	$38.84 - $51.31 $5,010 - $6,618	129 Added 0.67%	19,477 $884,000
Q1 2021 May 04, 2021	BUY	$39.51 - $51.45 $148,162 - $192,937	3,750 Added 24.04%	19,348 $807,000
Q4 2020 Feb 10, 2021	BUY	$25.81 - $43.62 $14,066 - $23,772	545 Added 3.62%	15,598 $666,000
Q3 2020 Nov 05, 2020	BUY	$25.74 - $29.63 $4,427 - $5,096	172 Added 1.16%	15,053 $396,000
Q2 2020 Aug 12, 2020	BUY	$16.25 - $26.81 $241,816 - $398,959	14,881 New	14,881 $399,000

543

125M

294K

180K

Ticker HALO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 139,288,992
Market Cap $6.62B
Description
Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...

Get notified when there are updates to the investment portfolio of Bank Of Marin, based on Form 13F filings with the SEC.

Stay updated on Bank Of Marin with notifications on news.